6/6/2016 | PP | StemCells cancels plans for its $30 million rights offering of stock
|
5/23/2016 | PP | StemCells registers $30 million of common stock for rights offering
|
3/9/2016 | PP | StemCells prices $8.1 million public sale of units at $0.30 per unit
|
3/9/2016 | PP | StemCells announces plans to conduct public sale of shares, warrants
|
6/1/2015 | PP | StemCells greenshoe exercised for $26.93 million public units offering
|
4/27/2015 | PP | StemCells prices $25 million public units offering at $0.70 per unit
|
4/23/2015 | PP | StemCells reports plans to price public offering of its common shares
|
7/15/2014 | PP | StemCells negotiates $20 million registered direct offering of units
|
10/8/2013 | PP | StemCells greenshoe exercised for $18.63 million public sale of units
|
10/2/2013 | PP | StemCells prices $16.97 million public sale of units at $1.45 each
|
10/1/2013 | PP | StemCells reports plans to price public offering of shares, warrants
|
6/4/2013 | PP | StemCells could take in $30 million through share purchase agreement
|
4/9/2013 | PP | StemCells secures $10 million via 6% loan through Silicon Valley Bank
|
12/28/2012 | PP | Stemcells lifts at-the-market equity offering to about $56.7 million
|
12/16/2011 | PP | StemCells prices $10 million public offering of stock and warrants
|
12/15/2011 | PP | StemCells intends to price public offering of its shares with warrants
|
1/7/2011 | PP | StemCells publicizes $10 million registered direct offering of shares
|
9/21/2010 | PP | StemCells nixes plans for $4.33 million tranche of $6.06 million deal
|
6/30/2010 | PP | New Issue: StemCells to sell $6.06 million of shares in registered direct offering
|
6/30/2010 | PP | Market Commentary: StemCells to sell stock to Seaside; Solargen wraps convert offering; InterRent seals placement
|
10/28/2009 | PP | New Issue: StemCells negotiates $12.5 million registered direct offering of stock
|
10/28/2009 | PP | Market Commentary: Park brings registered offering; Coachmen inks $20 million deal; StemCells seeks $12.5 million
|
11/12/2008 | PP | New Issue: StemCells aims for $20 million in direct offering of shares
|
11/12/2008 | PP | Market Commentary: ARYx wraps $21.59 million placement; StemCells, Endocare offer stock; Commerce offers stock, assets
|
6/24/2008 | CVHY | StemCells files $100 million shelf
|
11/8/2006 | BT | Market Commentary: Catalyst higher on debut; Hollis-Eden off 19% on PIPE; stem cell names better; Trimeris rises 23%
|
11/1/2006 | BT | StemCells 3Q net loss rises to $4.9 million, cash totals $55.4 million
|
10/31/2006 | BT | StemCells: negative cash flow, lack of product revenue continue
|
8/29/2006 | BT | StemCells Inc. grants license to Stem Cell Therapeutics
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/1/2006 | BT | StemCells says Q2 net loss hits $3.99 million
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
4/4/2006 | PP | Market Commentary: United Fuel wraps $8.75 million PIPE as part of merger; SyntheMed raises $6 million in stock deal
|
4/3/2006 | PP | Market Commentary: StemCells awaits completion of $35.84 million direct stock deal; Syntax-Brillian raises $15 million
|
4/3/2006 | BTPP | New Issue: StemCells prepares to close $35.84 million direct placement of stock
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
3/9/2006 | BT | StemCells gets board OK to start phase 1 clinical trial in Batten disease
|
10/20/2005 | BT | StemCells gets OK to begin phase I trial for Batten disease treatment
|
10/4/2005 | BT | Stemcells files $100 million stock shelf
|
9/30/2005 | BT | StemCells moves to Nasdaq National Market
|
9/27/2005 | BT | StemCells applies to list on Nasdaq National Market
|
7/29/2005 | BT | Market Commentary: Advanced Life Sciences, Avalon IPOs delayed; ZymoGenetics on deck for Wed; stem cell names rise
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|